[Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives].
Besides the management of symptoms of osteoarthritis, a lot of interest was raised for molecules aiming at slowing down the structural progression of the disease. This paper summarizes the currently available data allowing to discuss the efficacy and tolerance of these chemical entities.
Reginster
J Y
JY
Service de Santé Publique et d'Epidémiologie, Centre Collaborateur Organisation Mondiale de la Santé pour les Aspects de Santé Publique des Maladies Rhumatismales, Liège.
Henrotin
Y
Y
D000880:Anthraquinones / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D002807:Chondroitin / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D005944:Glucosamine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*
D000880:Anthraquinones; D000894:Anti-Inflammatory Agents, Non-Steroidal; C025292:diacerein; D006820:Hyaluronic Acid; D002807:Chondroitin; D005944:Glucosamine